DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 10/16/2019 --Nephropathic Cystinosis Market Insights, Epidemiology and Market Forecast-2028

1. Cystinosis affects males and females in equal numbers. The disorder is estimated to occur in 1 in 100,000-200,000 people in the general population.
2. Cystinosis is the most common cause of renal Fanconi syndrome in children and accounts for approximately 5 percent of all childhood cases of kidney failure.
3. Nephropathic Cystinosis incidence is approximately 1:150,000 to 200,000 live births and its prevalence is approximately 1.6 per million population.

(Albany, US) DelveInsight launched a new report on Nephropathic Cystinosis Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Nephropathic Cystinosis market report covers a descriptive overview and comprehensive insight of the Nephropathic Cystinosis epidemiology and Nephropathic Cystinosis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Nephropathic Cystinosis market report provides insights on the current and emerging therapies.
3. Nephropathic Cystinosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Nephropathic Cystinosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Nephropathic Cystinosis market.

Request for sample pages

"Infantile (Nephropathic Cystinosis) is the most common form of the disease, accounting for 95 % of cases."

The Nephropathic Cystinosis treatment is directed toward the specific symptoms that are apparent in each individual and is best treated by a team of specialists, who have knowledge about the disease, and who can offer supportive and symptomatic care. Care is directed toward relieving the symptoms of the disease. Cystine Depleting Therapies are now available for the Nephropathic Cystinosis treatment.
The ultimate goal of the Nephropathic Cystinosis treatment is to reduce the cystine levels in the body. The treatment approach involves cystine depleting therapies, symptomatic medications, and kidney transplant in severe cases. There are two cystine depleting therapies which are approved by the FDA for the treatment of this disease including Cystagon (Mylan Pharmaceuticals) and Procysbi (Horizon Pharma USA, Inc.). Cystagon (Mylan Pharmaceuticals) is approved for Nephropathic Cystinosis treatment in adults and children. It reacts with cystine to form another amino acid, called cysteine, and a compound called a cysteine-cysteamine salt. The body is able to remove this salt from the cells. The amount of cystine in the organs is therefore reduced, and this limits the damage to these organs.
PROCYSBI (Horizon Pharma USA, Inc.) is the other candidate which is approved for Nephropathic Cystinosis treatment in adult and pediatric patients 2 years of age and older. It participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis. Both of the
therapies have received orphan drug designation from the USFDA. Apart from these therapies, certain symptomatic treatment is also advised and consequently happens to occupy a considerable share in the overall treatment landscape. Infants and young children with cystinosis receive fluid and electrolytes, such as sodium and potassium. Vitamin D and phosphate salts are also given to deal with the problems of weaker bones. Diabetes is usually managed with a low-sugar diet, insulin, or other medicines that help control sugar in the blood. In severe cases where none of the therapies is effective, kidney transplant is recommended.
In a nutshell, it can safely be assumed that the present market space for Nephropathic Cystinosis treatment is not going to undergo any dynamic changes during the coming years due to lack of a robust pipeline and there are ample opportunities for companies currently investing in the research and development activities aimed at providing a curative treatment option for patients suffering from this disease during the forecast period [2019-2028].

Table of contents

1. Report Introduction
2. Nephropathic Cystinosis Market Overview at a Glance
3. Nephropathic Cystinosis Disease Background and Overview
4. Nephropathic Cystinosis Epidemiology and Patient Population
5. Nephropathic Cystinosis epidemiology by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 - Epidemiology (2017-2028)
5.3. Germany-Epidemiology (2017-2028)
5.4. France-Epidemiology (2017-2028)
5.5. Italy-Epidemiology (2017-2028)
5.6. Spain-Epidemiology (2017-2028)
5.7. United Kingdom-Epidemiology (2017-2028)
5.8. Japan-Epidemiology (2017-2028)
6. Nephropathic Cystinosis Treatments & Medical Practices
7. Nephropathic Cystinosis Marketed Products
7.1. Cystagon: Mylan Pharmaceuticals
8. Nephropathic Cystinosis Market Size
9. 7MM: Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. Italy Market Size
9.5. Spain Market Size
9.6. United Kingdom Market Size
9.7. Japan Market Size
10. Market Drivers
11. Market Barriers
12. Report Methodology

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight